Trial Profile
Copy of A Phase II Trial of Pembrolizumab (Anti PD-1) Therapy Combined With Sargramostim (GM-CSF) in Unresectable or Metastatic Melanoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 24 May 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Sargramostim (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 19 May 2023 Status changed from recruiting to withdrawn prior to enrolment.
- 06 Jul 2022 Planned End Date changed from 9 Jun 2023 to 9 Jun 2025.
- 06 Jul 2022 Planned primary completion date changed from 10 Jun 2022 to 10 Jun 2024.